An Army ranger is running retreats using psilocybin to treat combat veterans before the psychedelic gains formal regulatory approval, capitalizing on growing scientific interest in the compound's potential for post-traumatic stress disorder.
Jesse Gould, 38, served three combat deployments in Afghanistan and sustained traumatic brain injuries from concussive blasts. The experience left him with severe PTSD and drove him to drink heavily most nights as a coping mechanism.
Conventional treatment disappointed him. Traditional medication and talk therapy, Gould said, function as maintenance rather than genuine recovery. He found himself unwilling to accept a lifetime of pharmaceutical dependence at an age when he believed real healing was still possible.
Psilocybin, the active compound in so-called magic mushrooms, has drawn serious attention from researchers studying its effects on traumatic symptoms. Early clinical findings suggest potential therapeutic applications, though the substance remains tightly controlled at the federal level.
Gould's decision to operate retreats before FDA approval reflects a broader tension in the field: as states move toward decriminalization or expanded access, some practitioners are moving faster than regulators. Researchers caution that while the science appears promising, expansion without proper oversight carries risks.
The retreats occupy a legal gray zone, operating in jurisdictions where psilocybin carries reduced penalties or exists in a regulatory gap. Veterans seeking alternatives to conventional treatment increasingly view them as viable options, even as the medical and legal landscape remains unsettled.
Federal approval of psilocybin-based treatments could still be years away, leaving practitioners like Gould to navigate murky legal terrain while serving a population desperate for more effective solutions.
Comments